Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Development of a digital microfluidic platform to identify and target single cells from a heterogeneous cell population for lyses in an ultra-low volume

EF 2016-17

Résumé
Genetic abnormalities are a leading cause of death among Canadian newborns and infants. The standard-of-care for prenatal diagnosis of genetic abnormalities is (1) maternal blood tests and fetal ultrasound to screen for "high-risk" pregnancies, followed by (2) a diagnostic test on fetal cells requiring either insertion of a needle through the abdomen or vaginal surgery to confirm the results. The latter procedures carry a risk of miscarriage, require experienced medical personnel, are very expensive, and do not provide results until late in the pregnancy. There is clearly a need for safe (less invasive), less expensive prenatal diagnostic techniques that are able to provide relevant information at earlier stages of pregnancy. Mount Sinai Hospital (MSH) in Toronto runs the largest prenatal diagnosis center in Canada and one of the largest in North America. Scientists and physicians at MSH have developed a method to collect and isolate fetal cells non-invasively, using a technique similar to a routine PAP smear. In this proposal, techniques will be developed to rapidly and reproducibly isolate and analyze these cells for prenatal diagnosis of genetic abnormalities using microfluidics and genomic analysis. If successful, the techniques described here could completely transform the way prenatal diagnosis is delivered in Canada and around the world. That is, risk-associated, expensive, invasive diagnostics available after 12-15 weeks of pregnancy would be replaced with safe, inexpensive, non-invasive diagnostics available as early as after 5 weeks of pregnancy. This will result in higher coverage of the population, reduced patient anxiety, increased medical options for at-risk pregnancies, and significant reductions in health care costs. Canadians will also benefit from the formation of a promising prenatal diagnostic startup company, attracting investments and bringing job opportunities into Canada's burgeoning high-tech/biotech sector.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
362488
Name
Lamanna Julian
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Clinical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Development of a digital microfluidic platform to identify and target single cells from a heterogeneous cell population for lyses in an ultra-low volume
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Assay Development; Digital Microfluidics; Genomics; Non-Invasive Prenatal Diagnostic; Single-Cell Analysis
Abstract
Genetic abnormalities are a leading cause of death among Canadian newborns and infants. The standard-of-care for prenatal diagnosis of genetic abnormalities is (1) maternal blood tests and fetal ultrasound to screen for "high-risk" pregnancies, followed by (2) a diagnostic test on fetal cells requiring either insertion of a needle through the abdomen or vaginal surgery to confirm the results. The latter procedures carry a risk of miscarriage, require experienced medical personnel, are very expensive, and do not provide results until late in the pregnancy. There is clearly a need for safe (less invasive), less expensive prenatal diagnostic techniques that are able to provide relevant information at earlier stages of pregnancy. Mount Sinai Hospital (MSH) in Toronto runs the largest prenatal diagnosis center in Canada and one of the largest in North America. Scientists and physicians at MSH have developed a method to collect and isolate fetal cells non-invasively, using a technique similar to a routine PAP smear. In this proposal, techniques will be developed to rapidly and reproducibly isolate and analyze these cells for prenatal diagnosis of genetic abnormalities using microfluidics and genomic analysis. If successful, the techniques described here could completely transform the way prenatal diagnosis is delivered in Canada and around the world. That is, risk-associated, expensive, invasive diagnostics available after 12-15 weeks of pregnancy would be replaced with safe, inexpensive, non-invasive diagnostics available as early as after 5 weeks of pregnancy. This will result in higher coverage of the population, reduced patient anxiety, increased medical options for at-risk pregnancies, and significant reductions in health care costs. Canadians will also benefit from the formation of a promising prenatal diagnostic startup company, attracting investments and bringing job opportunities into Canada's burgeoning high-tech/biotech sector.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lamanna, Julian
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~